hypothesize that patients with symptomatic PAD will express several diagnostic cardiac markers of CAD in the absence of acute coronary syndrome (ACS).
Objective: This study sought to assess clinical outcomes of a single-center experience following drug-coated balloon (DCB) angioplasty in patients with TransAtlantic Inter-Society Consensus (TASC) II types C and D femoropopliteal peripheral artery disease (PAD) .
Methods: This retrospective study evaluated the patients who underwent DCB angioplasty for femoropopliteal PAD at our center between 2010 and 2016, with at least 1 year of follow-up. Of 424 patients with DCB-treated femoropopliteal disease, 152 were classified as TASC II type C or D. Demographics and comorbidities including age, sex, smoking status, hypertension, diabetes, and dialysis were recorded, alongside intervention details. Freedom from target lesion revascularization (TLR) within 1 year of interventionddefined as requiring bypass surgery or repeated percutaneous endovascular interventiondwas the primary outcome. Secondary outcomes included major above-knee or belowknee amputation and death.
Results: We analyzed 152 patients, excluding 13 because of immediate reintervention, amputation, bypass surgery, or death within 30 days of intervention. Of these 139 patients, 92 (66%) were type C and 47 (34%) were type D, with a mean treated lesion length of 18 6 6 cm; 75% were current or past smokers, 83% had hypertension, 63% had diabetes, and 5% were on dialysis. The dominant indication (45%) was severe claudication (Rutherford class 3), the remaining 55% being Rutherford class 4 to 6. De novo lesions made up 62% of cases, with in-stent stenosis or occlusions and recurrent stenosis each representing 19%; 27% of lesions were simultaneously treated with a short bare stent or drug-eluting stent, and 46% had multifocal disease treated as part of the procedure. At 1 year, 2% of patients had major amputation, and mortality was 12%. TLR at 1 year was 24% (33/139; Fig) .
Conclusions: Freedom from TLR in this cohort of patients with TASC II types C and D PAD was found to be 88% at 6 months and 76% at 12 months. Our initial results show that DCBs have a promising role in management of complex femoropopliteal disease. Table  I . In-hospital mortality was 8.3% (5/60). Postoperative myocardial infarction, stroke, and renal failure requiring dialysis occurred in four cases (6.7%), two cases (3.3%), and one case (1.7%), respectively. Spinal cord injury (SCI) was the most common complication, occurring in 10 (16.7%) patients, of which 4 cases were transient. Table II provides the characteristics of patients who developed SCI vs no-SCI cases.
Conclusions: This consecutive single-center experience demonstrates that B/F-EVAR may be safely performed with a high technical success rate. SCI is a common complication after B/F-EVAR, and despite intraoperative measures to minimize SCI rate in high-risk patients, the incidence has not decreased.
Author Disclosures: R. Rocha: BEVAR grafts done with special access approval, A. Gorman: BEVAR grafts done with special access approval, E. Binkowski: BEVAR grafts done with special access approval, M. Ouzounian: BEVAR grafts done with special access approval, K. Tan: BEVAR grafts done with special access approval, T. Lindsay: BEVAR grafts done with special access approval. Objective: Retrograde in situ laser fenestration of the left subclavian artery (LSA) or common carotid artery during emergent thoracic endovascular aortic repair (TEVAR) is an innovative method to revascularize arch branches for diverse thoracic aortic diseases. This study provides an update on our expanded experience with extended follow-up to determine the efficiency and durability of this technique.
In Situ Laser Fenestration for Arch Branch
Methods: Patients who underwent TEVAR with aortic arch branch revascularization from 2009 through 2018 were retrospectively reviewed. After TEVAR, the endograft was deployed over a branch orifice, in situ retrograde laser fenestration was performed through retrograde access, and a balloon-expandable covered stent was deployed in the LSA or common carotid artery. Postoperative imaging with computed tomography angiography was performed to assess branch patency, endoleaks, and fenestration-related reinterventions.
Results: TEVAR with laser fenestration was successfully performed in 60 patients (38 men; mean age, 61 years) in an urgent or emergent setting for diverse thoracic aortic diseases including 16 ruptures. Seventeen had acute complicated type B aortic dissection, 15 had intramural hematoma, and 17 had chronic dissection. TEVAR was done in zone 0 in 2 patients, in zone 1 in 7 patients, and in zone 2 in 51 patients. A balloon-expandable covered stent was placed across the fenestration into 56 LSAs, 3 left coronary arteries, and 1 right coronary artery. Mean length of stay was 9 days. Mean follow-up was 2.44 years. In-hospital mortality was 8.3%. Stroke rate was 3.3% (2/60), and three had permanent paraplegia. Follow-up computed tomography angiography demonstrated 100% primary patency of branch stents. There was no type III endoleak, but three type IC endoleaks required early coiling (one) and late restenting (two) for a 5.45% fenestration-related major reintervention rate.
Conclusions: In situ retrograde laser fenestration is a rapid, effective, and durable method to revascularize arch branches during emergent TEVAR. The high technical success, low fenestration-related morbidity and reintervention rate, and excellent branch stent patency support use of this versatile technique. Objective: The role of nonoperative management of blunt traumatic thoracic aortic injury (BTAI) continues to evolve. Our objective was to summarize the growing body of literature on this practice.
Methods: A systematic search of PubMed and Embase was completed to identify original articles reporting retrospective or prospective primary data on BTAI patients managed without surgical intervention during their index hospitalization. Articles meeting inclusion criteria were selected on the basis of abstract and full-text screening. Study selection and data abstraction were performed in duplicate, with discrepancies resolved by a third reviewer.
Results: Of 2162 identified studies, 74 were included and reported on 8606 BTAI patients who were managed nonoperatively between 1970 and 2016. Only one study was prospective. The median nonoperative sample size was 11 patients. Characterization of injury grade differed across studies, and injuries to the ascending aorta or aortic arch were often included in outcome summaries. Follow-up varied widely from 1 day to 8 years. Among the 59 studies with information on injury grade (n ¼ 1250 patients), injury healing or improvement on follow-up imaging was reported in 226 patients (18%), who mostly had intimal tears. Injury progression or requirement of a subsequent procedure was reported in 69 patients (5.5%), along with 37 aorta-related deaths (16%).
Conclusions: An increasing number of reports support nonoperative management of intimal tears, consistent with Society for Vascular Surgery guidelines. However, retrospective interpretation of the intention of treatment, heterogeneous injury characterization, and variable follow-up remain major limitations to the informed use of nonoperative management across all BTAI grades.
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